(Total Views: 570)
Posted On: 08/25/2023 1:23:35 AM
Post# of 148899
Another idiotic DM from truths.
My reply.
Quote:
maybe you should also discuss the phase 3 trodelvy / keytruda trial, a combo that has addiitve MOAs. that'll raise the bar assuming success. it also presents a complication that has shot cytodyn in the foot already... a moving target tnbc SOC. on the other hand... cytodyn is so many years away from a p3 human trial vs SOC for any tnbc indication that any discussion about this is silly, right? i mean, SOC could change several times before cytodyn ever gets into a p3 combo. time is not on their side.
My reply.
Quote:
Trodelvy is a topoisomerase inhibitor that stops DNA repair in tumor cells. Leronlimab stops DNA repair by downregulating GRP78. Also an abundance of GRP78 can inhibit the effect of topoisomerase inhibitors so leronlimab should be more effective than Trodelvy in that regard.
Leronlimab downregulates the receptor for PD - L1 (Keytruda's target) called PD -1. So leronlimab does what both Trodelvy and Keytruda do and even more.
(22)
(0)Scroll down for more posts ▼
